SUMO2/3 Antibody

The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Titering of the SUMO2/3 antibody may be required for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer�s disease.

Purified

Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*

6613, 6612

Recombinant human SUMO2 protein was used as the immunogen for this SUMO2/3 antibody. This antibody reacts with both SUMO2 and SUMO3.

This SUMO2/3 antibody is available for research use only.

Predominantly nuclear with some cytoplasmic staining

Protein G purified